Premium
Juvenile generalized pustular psoriasis treated with etanercept
Author(s) -
Fialová Jorga,
Vojáčková Nadežda,
Vaňousová Daniela,
Hercogová Jana
Publication year - 2013
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12065
Subject(s) - medicine , etanercept , psoriasis , methotrexate , acitretin , generalized pustular psoriasis , dermatology , tolerability , exacerbation , pustular psoriasis , methylprednisolone , adverse effect , tumor necrosis factor alpha
An 8‐year‐old boy with general pustular psoriasis ( GPP ) and iatrogenic secondary Cushing syndrome was treated successfully with etanercept after he had failed on acitretin, methotrexate, and methylprednisolone therapy. GPP is a severe and very rare variant of psoriasis in children often accompanied by life‐threatening complications. Retinoids, cyclosporine, methotrexate, or dapsone used in a small number of case series and case reports were effective. Etanercept is a recombinant human tumor necrosis factor‐alpha ( TNF ‐alpha) receptor protein fused with F c portion of IgG1 that binds to TNF ‐alpha, approved by F ood and D rug A dministration for the treatment of moderate‐to‐severe plaque psoriasis in children and teens who have not responded to other psoriasis treatments. In our patient, etanercept demonstrated significant clinical response associated with long‐term efficacy without acute exacerbation, excellent tolerability, and good safety profile.